Medline Statistics
Total Valuation
Medline has a market cap or net worth of $53.91 billion. The enterprise value is $64.28 billion.
| Market Cap | 53.91B |
| Enterprise Value | 64.28B |
Important Dates
The next confirmed earnings date is Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medline has 1.31 billion shares outstanding.
| Current Share Class | 845.61M |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.83% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 48.73% |
| Float | 356.91M |
Valuation Ratios
The trailing PE ratio is 35.94 and the forward PE ratio is 26.67. Medline's PEG ratio is 5.75.
| PE Ratio | 35.94 |
| Forward PE | 26.67 |
| PS Ratio | 1.85 |
| Forward PS | 1.71 |
| PB Ratio | 3.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 54.13 |
| P/OCF Ratio | 36.58 |
| PEG Ratio | 5.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.12, with an EV/FCF ratio of 64.54.
| EV / Earnings | 66.55 |
| EV / Sales | 2.21 |
| EV / EBITDA | 21.12 |
| EV / EBIT | 31.73 |
| EV / FCF | 64.54 |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.65.
| Current Ratio | 4.41 |
| Quick Ratio | 2.34 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 3.98 |
| Debt / FCF | 12.69 |
| Interest Coverage | 2.34 |
Financial Efficiency
Return on equity (ROE) is 6.05% and return on invested capital (ROIC) is 6.04%.
| Return on Equity (ROE) | 6.05% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 6.04% |
| Return on Capital Employed (ROCE) | 5.55% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $647,556 |
| Profits Per Employee | $21,467 |
| Employee Count | 45,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Medline has paid $127.00 million in taxes.
| Income Tax | 127.00M |
| Effective Tax Rate | 10.57% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 38.39 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 57.94 |
| Average Volume (20 Days) | 9,283,438 |
Short Selling Information
The latest short interest is 27.64 million, so 2.10% of the outstanding shares have been sold short.
| Short Interest | 27.64M |
| Short Previous Month | 22.77M |
| Short % of Shares Out | 2.10% |
| Short % of Float | 7.75% |
| Short Ratio (days to cover) | 1.96 |
Income Statement
In the last 12 months, Medline had revenue of $29.14 billion and earned $966.00 million in profits. Earnings per share was $1.14.
| Revenue | 29.14B |
| Gross Profit | 7.54B |
| Operating Income | 2.03B |
| Pretax Income | 1.20B |
| Net Income | 966.00M |
| EBITDA | 3.04B |
| EBIT | 2.03B |
| Earnings Per Share (EPS) | $1.14 |
Balance Sheet
The company has $2.27 billion in cash and $12.64 billion in debt, with a net cash position of -$10.37 billion or -$7.89 per share.
| Cash & Cash Equivalents | 2.27B |
| Total Debt | 12.64B |
| Net Cash | -10.37B |
| Net Cash Per Share | -$7.89 |
| Equity (Book Value) | 19.35B |
| Book Value Per Share | 13.32 |
| Working Capital | 8.64B |
Cash Flow
In the last 12 months, operating cash flow was $1.47 billion and capital expenditures -$478.00 million, giving a free cash flow of $996.00 million.
| Operating Cash Flow | 1.47B |
| Capital Expenditures | -478.00M |
| Depreciation & Amortization | 1.02B |
| Net Borrowing | -4.13B |
| Free Cash Flow | 996.00M |
| FCF Per Share | $0.76 |
Margins
Gross margin is 25.86%, with operating and profit margins of 6.95% and 3.32%.
| Gross Margin | 25.86% |
| Operating Margin | 6.95% |
| Pretax Margin | 4.12% |
| Profit Margin | 3.32% |
| EBITDA Margin | 10.45% |
| EBIT Margin | 6.95% |
| FCF Margin | 3.42% |
Dividends & Yields
Medline does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 1.79% |
| FCF Yield | 1.85% |
Analyst Forecast
The average price target for Medline is $50.89, which is 24.00% higher than the current price. The consensus rating is "Buy".
| Price Target | $50.89 |
| Price Target Difference | 24.00% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (3Y) | 8.25% |
| EPS Growth Forecast (3Y) | 1.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medline has an Altman Z-Score of 2.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.29 |
| Piotroski F-Score | 3 |